30 closest matches · ranked by relevance
CTEPH · Pulmonary Embolism · Early Diagnosis
Primary: To Identify the Accuracy of Routine CTPA for the Distinction of CTEPH From Acute PE. — 70; 70 Sensitivity
Chronic Thromboembolic Pulmonary Hypertension
Primary: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes — 89289.89; 86548.72; 205707.83; 152911.57 ng/ml — p=<0.05
Pulmonary Hypertension
Primary: Change From Baseline to All Assessed Time Points in 6-minute Walk Test (6MWT) Distance — 8.4; 18.2; 17.7; 20.2 walk distance change from baseline (m)
Chronic Thromboembolic Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 72 Participants
Chronic Thromboembolic Pulmonary Hypertension
Primary: Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) at Rest. — 73.0; 87.2 percent of baseline PVR — p=0.0410
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Primary: Change in 6-minute Walk Test Distance After 24 Weeks — 45.43; 3.83 m — p=0.002
Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 153; 82; 77; 44 Participants
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Pulmonary Hypertension · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Pulmonary Hypertension
Primary: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16 — 38.9; -5.5 Meters — p=<0.0001
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Pulmonary Hypertension · Interstitial Lung Disease · Combined Pulmonary Fibrosis and Emphysema
Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 — -9.0; 6.0 meters — p=0.0043
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
Pulmonary Embolism · Acute Pulmonary Embolism · Sub-massive Pulmonary Embolism
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Pulmonary Arterial Hypertension
Primary: Change in 6-minute Walk Distance — 13.5 m
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
Portopulmonary Hypertension
Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
Pulmonary Arterial Hypertension
Primary: Number of Adverse Events — 450; 362; 126; 206 events
Pulmonary Embolism · Pulmonary Thromboembolism
Primary: Primary Endpoint: Composite Clinical Endpoint Constructed as a 5-Component Win Ratio — 52693; 10509 Number of Wins for the group
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56